A Phase 2, Randomized, Observer-Blind, Multicenter Study to Describe the Immunogenicity and Safety of Several Regimens Altering the Antigen and MF59 Adjuvant Content in a Monovalent Pandemic Influenza Vaccine in Healthy Pediatric Subjects 6 Months to < 18 Years of Age

Trial Profile

A Phase 2, Randomized, Observer-Blind, Multicenter Study to Describe the Immunogenicity and Safety of Several Regimens Altering the Antigen and MF59 Adjuvant Content in a Monovalent Pandemic Influenza Vaccine in Healthy Pediatric Subjects 6 Months to < 18 Years of Age

Not stated
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; Squalene (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms Pediatric Dose-ranging of aH5N1
  • Sponsors Seqirus
  • Most Recent Events

    • 04 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top